Introduction
============

Autism spectrum disorder (ASD) is characterized by impairments in social interactions and verbal and nonverbal communication, along with repetitive patterns of behaviors and interests. ASD prevalence has continued to increase over the last decades, affecting approximately 1% of the population worldwide.^[@ref1]^ Although its etiology is still unknown, it involves genetic, immunological, and environmental risk factors,^[@ref2]^ leading to severe alterations in neuronal network formation early in life. Multiple epidemiological studies provide strong evidence for a connection between maternal infection during the first two trimesters of pregnancy and the development of ASD in offspring.^[@ref4]^ For instance, inflammatory cytokines could reach the fetal brain and alter key physiological and neurodevelopmental processes.^[@ref7]^ In addition, mothers with autoimmune disorders show an increased risk of giving birth to children with ASD,^[@ref8]^ supporting the etiological role of an autoimmune dysfunction in patients with ASD. Consistently, autoantibodies against fetal brain targets have been identified in the sera of ASD patients\' mothers.^[@ref9]^ These autoantibodies, for which targets are yet undefined, produce long-term behavioral consequences in newborn rodents if injected into the dams.^[@ref10]^

Autoantibodies against neuronal receptors have been increasingly identified in neuropsychiatric disorders and today constitute one of the hottest topics in psychiatry.^[@ref11]^ This has generated great hope for a better understanding of the molecular dysfunctions underlying these disorders and identification of patients who could benefit from immunotherapy. The best-characterized disorder in which autoantibodies directed against brain targets directly contribute to psychiatric symptoms is anti-*N*-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. The NMDAR autoantibodies (NMDAR-Ab) target an extracellular epitope of the GluN1-NMDAR subunit and profoundly alter receptor trafficking and signaling.^[@ref12]^ NMDAR-Abs were also detected in two adults with ASD who consequently developed anti-NMDA encephalitis.^[@ref14]^ Intriguingly, it was reported that a 9-year-old boy initially suffering from an anti-NMDAR encephalitis subsequently exhibited ASD-like symptoms,^[@ref15]^ suggesting a potential link between the NMDAR-Ab and the emergence of ASD. Here, we investigated the presence and putative molecular pathogenecity of NMDAR-Ab in a cohort of ASD patients, using the single-particle tracking method in live dissociated hippocampal neurons.

Materials and methods
=====================

Patient cohort
--------------

ASD patients and controls (healthy) were recruited via the InFoR-Autism program (I\'lnserm, la Fondation FondaMental et Roche - Autism), which is a 2-year, multicenter, longitudinal, non-drug study. Children, adolescents, and adult patients presenting with ASD, and age- and gender-matched healthy subjects were recruited in three French specialist centers for ASD under the auspices of the FondaMental Foundation (Créteil, Paris and Bordeaux). Subjects were evaluated with a battery of diagnostic tools, including a French version of the ADI-R (Autism Diagnostic Interview - Revised), and the ADOS (Autism Diagnostic Observation Schedule). All adult subjects had several blood samplings planned over the course of the study for genetic, biochemical, and immunological studies.

Detection of NMDA-receptor autoantibodies (NMDAR-Ab) in sera
------------------------------------------------------------

We tested serum samples of a subpopulation of the InFor-Autism cohort (24 ASD patients and 18 healthy controls) for the presence of NMDAR-Ab using a cell-based assay previously described in the literature.^[@ref12]^ Briefly, human embryonic kidney cells (HEK293) were transfected with the GluN1-NMDAR subunit fused to green fluorescent protein (GFP), along with the GluN2B-NMDAR subunit. After a 48-hour expression period, live HEK cells were incubated 3 hours with the subjects\' sera (1/20 in saturation buffer). Then, fixed HEK cells were incubated with anti-human type G immunoglobulin (IgG) coupled to Alexa 555. Viewed by fluorescence microscopy, an overlap of both green and red staining indicated a subject\'s seropositivity for NMDAR-Ab. Samples were considered seropositive for NMDAR-Ab when a clear overlap was confirmed by three different readers in three independent assays.

Primary cell culture and single quantum dot (QD) tracking
---------------------------------------------------------

As previously described in the literature,^[@ref12]^ dissociated hippocampal neurons were prepared from E18 Sprague-Dawley rats. Quantum dot (QD) tracking of the endogenous GluN2A-NMDAR subunit was performed on live hippocampal neurons at day 13 to day 15 in vitro. Neurons were first incubated (30 min) with purified IgG (5μg/mL) from either the seropositive ASD patient (ASD+), the seropositive healthy subject (healthy+), or seronegative healthy subjects (healthy-) *([Figure 1](#DialoguesClinNeurosci-19-65-g001){ref-type="fig"}).* QD labeling and microscopy were performed as previously described.^[@ref12]^ Briefly, hippocampal neurons were incubated (10 min) with anti-GluN2A-NMDAR subunit antibodies (Agro-Bio, 1/200). Neurons were then washed and incubated (10 min) with QDs coupled to an anti-rabbit F(ab) fragment (Life Technologies, 1/20 000). Mitotracker Green (Life Technologies, 1/20000) was used as an endogenous synaptic marker. Images were obtained with an acquisition time of 50 milliseconds with up to 500 consecutive frames. The instantaneous diffusion coefficient, *D*, was calculated for each trajectory, from linear fits of the first four points of the mean square displacement (MSD) versus time function using MSD(t)= \<r2\>(t)= 4Dt.

![NMDAR autoantibodies from the seropositive healthy subject (Healthy+) and the seropositive ASD patient (ASD+) do not differ in their capacity to alter synaptic NMDAR dynamics. (**A**) Schematic representation of the experimental design. Before tracking GluN2A-NMDAR-QD complexes, hippocampal cultures (13 to 15 days in vitro) were incubated for 30 minutes with different purified type G immunoglobulin (IgG) samples from a seropositive healthy subject from the cohort (Healthy+), a seropositive ASD patient from the cohort (ASD+), or three pooled healthy seronegative subjects (Healthy-). (**B**) Representative trajectories of GluN2A-NMDAR-QD complexes (500 frames, 50 ms acquisition) at the plasma membrane in the presence of NMDAR-Ab from Healthy+ and ASD+. Synapses (in green) are identified with Mitotracker. Scale bar: 500 nm. (**C**) Synaptic mean square displacement (MSD) of GluN2A-NMDAR-QD complexes in the absence (Healthy-) or presence (Healthy+, ASD+) of NMDAR-Ab. (**D**) Cumulative frequency of the synaptic GluN2A-NMDAR-QD complexes diffusion coefficient in the absence (Healthy-) or presence (Healthy+, ASD+) of NMDAR-Ab. (**E**) Comparison of GluN2A-NMDAR diffusion coefficient in the absence (Healthy-) or presence (Healthy+, ASD+) of NMDAR-Ab at glutamate synapses (median diffusion coefficient ࢱ 25%-75% IQR, Healthy- = 0.107 μm^2^/s, IQR= 0.034-0.197 μm^2^/s, n= 492; Healthy+ = 0.089 μm^2^m/s, interquartile range (IQR) = 0.036-0.185 μm^2^/s, n= 490; ASD+ = 0.102 μm^2^/s, IQR= 0.039-0.186 μm^2^/s, n= 555; *P=* 0.81 Kruskal-Wallis test). Anti-GluN2A, anti-*N*-methyl-D-aspartate receptor 2A; ASD, autism spectrum disorder; ASD+, seropositive autism spectrum disorder patient; Cumui. freq., cumulative frequency; Diff. coeff., diffusion coefficient; Healthy+, seropositive healthy subject; Healthy-, seronegative healthy subject; IgG, type G immunoglobulin; QD, quantum dot; MSD, mean square displacement; NMDAR, *N*-methyl-D-aspartate receptor; NMDAR-Ab, *N*-methyl-D-aspartate receptor autoantibody.](DialoguesClinNeurosci-19-65-g001){#DialoguesClinNeurosci-19-65-g001}

Results
=======

Using a classical cell-based assay, as described in the literature,^[@ref12]^ we investigated the presence of circulating NMDAR-Ab in healthy subjects and patients with ASDs. Out of the 42 normal subjects and patients tested for NMDAR-Ab, only one healthy subject free of any neurological or psychiatric disorder and one ASD patient were seropositive for NMDAR-Ab. This ASD patient is a 53-year-old man, initially examined at the Expert Center for Autism (*Centre Expert Asperger,* Créteil, France). On initial evaluation, the patient was well oriented in time and space. However, his speech volume and production was low, with monotonous prosody. The affect was restricted in range, flat and relatively incoherent to his described internal state. Thought process and content were normal. There was no suicidal ideation, delusions, hallucinations, or memory trouble at the time of the interview. The patient presented with a specific phobia and a delayed sleep phase syndrome. A lack of nonverbal and verbal communication was noted (see ADOS score in *Table I*). The patient exhibited alexithymia, difficulties in apprehending intentions, and a lack of empathy, consistent with an altered theory of mind. Sensory peculiarities (hypersensitivity to noise and hyposensitivity to low temperatures) were also reported. These symptoms met criteria for ASD without intellectual deficiency (*Table II*). ASD symptoms emerged during childhood, as the patient was isolated, suffered from severe social anxiety, and acquired speech later than average. In adulthood, the patient had recurrent episodes of panic attacks, generalized anxiety, and suffered from two major depressive disorder episodes without psychotic symptoms (at age 37 and 43). The patient had no history of auditory or visual hallucination, no delusional thinking, no suicidal attempts, and the neurological examination was normal.

###### ADOS (Autism Diagnostic Observation Schedule) 1 module 4 algorithm scores from the autism spectrum disorder (ASD+) patient.

  **Domains**                                    **Scores**
  ---------------------------------------------- ------------
  Language and communication                     
  A-4                                            0
  A-8                                            1
  A-9                                            0
  A-10                                           1
  Total communication                            2
  Reciprocal social interaction                  
  B-1                                            0
  B-2                                            1
  B-6                                            2
  B-8                                            0
  B-9                                            0
  B-10                                           1
  B-11                                           1
  Total reciprocal social interaction            5
  Total communication + social interaction       7
  Imagination/creativity                         
  C-1                                            1
  Stereotyped hebavior and restricted interest   
  D-1                                            0
  D-2                                            0
  D-4                                            0
  D-5                                            0
  Total                                          0
  Other abnormal behaviors                       
  E-1                                            0
  E-2                                            0
  E-3                                            0
  Total                                          0

###### Intellectual quotient (IQ) and Hamilton Anxiety and Depression Scales scores from the seropositive autism spectrum disorder (ASD+) patient. PRI, Perceptual Reasoning Index; PSI, Processing Speed Index; WAIS IV, Wechsler Adult Intelligence Scale IV; WMI, Working Memory Index; VCI, Verbal Comprehension Index

  --------------------------- --------- ---------
                                        VCI=108
                                        PRI=122
  Cognitive level             WAIS IV   WMI=120
                                        PSI=137
  Hamilton anxiety score                1
  Hamilton depression score             0
  --------------------------- --------- ---------

We then explored the possibility that the circulating NMDAR-Ab from this patient, and not from the healthy+ subject, altered NMDAR trafficking and signaling,^[@ref12]^ possibly contributing to the symptomatology.^[@ref15]^ For this, NMDAR-Ab IgGs were purified from the ASD patient and the seropositive healthy subject, and both IgGs were used to perform single-nanoparticle tracking on surface NMDAR in live hippocampal neurons (*Figure 1A*). Incubation for at least 30 minutes with purified IgGs from either the ASD patient or the seropositive healthy subject did not alter the surface trafficking of GluN2A-NMDAR when compared with seronegative healthy subjects (*Figure 1B-E*). This was assessed by measuring the MSD curves and instantaneous diffusion coefficients of surface GluN2A-NMDAR (*Figure 1B-E*). Together, these data indicate that the NMDAR-Ab purified from the ASD patient or from a seropositive healthy subject do not alter the surface trafficking of NMDAR and thus probably have no effect on NMDAR signaling.

Discussion
==========

Regarding the accumulating evidence that immune imbalance could be one of the factors responsible for neurodevelopmental brain disorders such as ASD, we investigated the autoimmune status of a cohort of ASD patients. We reveal that a fraction of these patients exhibited a high content of circulating autoantibodies, reflecting an overall autoimmune dysregulation. Among the autoantibodies, we specifically explore the presence and molecular pathogenicity of NMDAR-Ab in ASD patients. Indeed, the report that a 9-year-old boy initially suffering from an anti-NMDAR encephalitis subsequently exhibited ASD-like symptoms^[@ref15]^ suggests an intriguing link between the NMDAR-Ab and the emergence of ASD. These autoantibodies were best characterized in anti-NMDAR encephalitis patients that exhibit, among others, psychotic symptoms and catatonia, followed by neurologic deterioration.^[@ref13]^ Using the innovative single-particle tracking approach, we explored with very high sensitivity whether the NMDAR-Ab from the ASD patient altered the trafficking of the NMDAR, as previously demonstrated with NMDAR-Ab purified from anti-NMDAR encephalitis patients.^[@ref12]^ Our data demonstrate that NMDAR-Ab from the ASD patient did not alter the basal trafficking of surface NMDAR in hippocampal glutamate synapses. Although this report is based on the molecular exploration from only one seropositive patient, it suggests that NMDAR-Ab isolated in ASD patients (or in healthy subjects) do not alter the NMDAR signaling and probably are not involved in the ASD etiology. Noteworthy, this finding is consistent with the fact that NMDAR-Ab induced major psychotic symptoms that were never diagnosed in this patient. However, other autoantibodies have been detected in ASD patients,^[@ref17]^ some with specific brain targets. Based on the pathological autoimmune status of this patient and the therapeutic benefit of immunotherapy in ASD patients,^[@ref17]^ it would be of great interest to screen for autoantibodies against other neuronal targets involved in brain cell communication and that have been related to ASD.
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